Eli Lilly and Co. stock gains as Houston plant expands GLP-1 capacity

Published on 09/23/2026 at 13:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly and Co. stock closed at USD 1,172.05 on September 22, 2026, after a 0.61 percent gain. Q2 revenue rose 47.7 percent to USD 22.97 billion.

Extreme Makroaufnahme eines hochpolierten Edelstahlflanschs mit O-Ring-Dichtung einer Vakuumkammer auf schwarzem Hintergrund — Lam Research US5324571083 Makro polierter Vakuumkammer Flansch mit O Ring Dichtung auf schwarzem Hintergrund, Illustration mit AI erstellt.

Eli Lilly and Co. stock (ISIN US5324571083) closed at USD 1,172.05 on the NYSE on September 22, 2026, up 0.61 percent from the previous session. The company had broken ground on a USD 6.5 billion Houston manufacturing facility on September 21, adding a concrete capacity milestone to the market's focus on GLP-1 demand.

Houston plant targets oral GLP-1 demand

According to Pharma Manufacturing on September 22, 2026, the Houston site will produce active pharmaceutical ingredients for Foundayo and other small-molecule medicines. The project forms part of a broader USD 50 billion domestic manufacturing investment and is expected to employ more than 600 people.

The investment matters because Foundayo generated USD 98 million in revenue during the second quarter of 2026, its first full quarter on the market, according to TheStreet on September 22, 2026. The new facility therefore links a current manufacturing commitment with an identifiable commercial product rather than only a long-term pipeline plan.

Q2 figures set a high benchmark

Lilly reported USD 22.97 billion in revenue for the quarter ended June 30, 2026, up 47.7 percent from USD 15.56 billion in the year-earlier quarter. The company also reported quarterly EPS of USD 8.38, compared with USD 6.31 a year earlier, and exceeded the USD 6.40 consensus estimate by USD 1.98, according to MarketBeat on September 22, 2026.

The comparison shows why capacity is central to the valuation: revenue growth of 47.7 percent and an EPS increase from USD 6.31 to USD 8.38 leave execution, supply and demand conversion as the next measurable tests. Lilly's fiscal 2026 EPS guidance stands at USD 35.50 to USD 36.50, while the current-year analyst expectation cited by MarketBeat is USD 36.54.

Stock remains below yearly high

The NYSE share price reached USD 1,180.47 during the September 22 session and remained below the 52-week high of USD 1,292.65. The same trading data show a 52-week low of USD 712.05, volume of 1.40 million shares and a market capitalization of about USD 1.10 trillion, all as of September 22, 2026.

MarketBeat lists a consensus rating of Moderate Buy and a consensus price target of USD 1,305.25 as of September 22, 2026. That target sits above the September 22 close, while the valuation still depends on whether GLP-1 demand, Foundayo adoption and manufacturing expansion convert into the earnings trajectory already reflected in fiscal 2026 expectations.

Next earnings date is October 29

Eli Lilly and Co. next earnings date is October 29, 2026, according to Ad-hoc-News on September 22, 2026. The September 22 NYSE close was USD 1,172.05, with the stock 9.33 percent below its 52-week high of USD 1,292.65.